MaxCyte, Angiogene CV gene therapy deal

MaxCyte (Rockville, Md.), a majority-owned subsidiary of EntreMed (ENMD), partnered with Angiogene (Montreal, Quebec) to research and develop a non-viral therapy to treat congestive heart failure (CHF...